# Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

> **NCT03347292** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 58 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Regorafenib(Stivarga, BAY73-4506)
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03347292
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-18
- **Primary completion:** 2020-12-17
- **Final completion:** 2022-09-06
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2023-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03347292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03347292, "Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03347292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*